Board and Management

Gerry Brown joined the Board in 2006 and was appointed Chairman of the Company in June 2006. He is Chairman of Quintiles Transnational EMEA and of NFT Distribution Holdings. He is also Senior Independent Director of both Forth Ports plc and Keller plc. He was formerly Chairman of Upol Ltd and a non-executive director of Vantec Ltd, CH Jones Ltd, Michael Gerson Ltd and Datrontech plc. His executive career included directorships with Exel Logistics plc, TDG plc and Tibbett & Britten plc.

Crispin Simon joined the Company in June 1998. After working at NM Rothschild and McKinsey & Company, he gained general management experience at senior executive level with Rexam plc (then Bowater) and then as President of the Endoscopy Division of Smith & Nephew plc, based in Boston, USA. Crispin Simon is a non-executive director of Imperial College Healthcare NHS Trust and a Governor of Port Regis School.

Jeremy Curnock Cook joined the Board in 1990. He is Executive Chairman of International Bioscience Managers Limited, an investment advisory company to the biotechnology industry, Managing Director of IB Australian Bioscience Fund Pty Ltd, a fund management company, and of Intersuisse Bioscience Managers Pty Ltd, a corporate advisory firm. He served as Managing Director of the Rothschild Bioscience Unit from 1987 until his retirement in 2000. Other directorships include: Chairman of Targeted Genetics Inc. (USA), and EACOM Timber Corp. (Canada); Director of Excalibur Group Holdings Ltd, Osteologix Inc. (USA), Aegera Therapeutics Inc. (Canada) and Hunter Immunology Limited (Australia).

Thomas Harris joined the Board in 2005. He is Vice Chairman of Standard Chartered Capital Markets Ltd, a director of SC (Korea) Bank, the UK-India Business Council, IFSL, Johnson Matthey plc and a Trustee of Asia House. He was Director General of Trade & Investment USA responsible for British business and technology promotion throughout the USA. He served as British Ambassador to Korea in Seoul, Deputy High Commissioner in Lagos, Nigeria and Commercial Counsellor in the British Embassy in Washington DC.

Anthony Weir was appointed to the Board on 1st January 2007. In October 2009 Tony was appointed Chief Operating Officer of Ingenix International and Chief Financial Officer of United Health UK, the healthcare consultancy arm of United Health Group, the US health insurance company. Tony has 20 years experience in life sciences including 10 years as Chief Financial Officer at Vernalis plc. Previously he was with PwC, Financial Training Limited and KPMG, has a degree in Mathematics from Oxford University and is a Fellow of the Institute of Chartered Accountants.

Anne Fairey joined the Board on 1 September 2008. Anne has been Director of Fairey Medical Ltd since 2003. Previously she was Medical Director of Novartis Pharmaceuticals UK Ltd. Anne qualified in Medicine from Southampton University and subsequently completed her Senior Registrar training in Medical Oncology before moving into the pharmaceutical industry in 1992. She was elected a Member of the Faculty of Pharmaceutical Medicine by distinction in 2004 and a Fellow of the Royal College of Physicians in 2006.

Peter Stratford was appointed to the Board in September 2002. Peter joined Biocompatibles in January 1990. After completion of development work in contact lens application, he joined the management team of the Cardiovascular Division at its creation in 1993. He took the role of Group Director Research and Development in 1998 and has since transitioned the Group to the current oncology products focus. Peter has a BSc in Chemistry, an MSc in Polymer Synthesis and a PhD in Pharmaceutical Synthesis.

John Sylvester joined the Company in June 2005 and was appointed to the Board on 1 July 2005. His career covers a series of commercial roles for Rio Tinto Zinc plc, ICI plc and English China Clays where he was General Manager for their European and Asian Operations. Previously he was with Baxter Healthcare where he was VP Marketing for their European Medication delivery business.

Ian Ardill, appointed to the Board in October 2004, joined Biocompatibles in January 2003 having spent the previous five years working for Novartis Pharmaceuticals in a variety of financial positions covering Financial Accounting, Systems Implementation, and Treasury. Prior to that, he worked for Letheby & Christopher, a subsidiary of Compass Group PLC; NHA International, a sales and management consultancy; and qualified as an accountant with Grant Thornton. He has a BSc in Accounting and Financial Analysis from Warwick University, England.

Paul Baxter is responsible for the management of the Company's Intellectual Property, provides contract management and supports the Company’s licensing activities. Paul has an MBA and is a Fellow of the Royal Society of Chemistry.

Andy Lewis is director of research projects both at the Farnham site and externally with academic and industrial collaborators. Andy has a BSc in Biochemistry and Chemistry, a PhD in Chemistry and has previous experience within Johnson & Johnson and ICI. He is Professor of Biomaterials & Drug Delivery at the University of Brighton, a fellow of the RSC and IOMMM, a Chartered Scientist and is named on over 180 scientific publications and patents.

Tim Maloney is responsible for the recently-acquired Siascopy technology. Tim has been with Biocompatibles since January of 1998 working in Cardiology, Interventional Radiology, Interventional Oncology, Oncology, and Business Development. Prior to Biocompatibles, Tim worked with C.R. Bard in Export, Cardiovascular, and Cardiology. Tim has a double B.A. in History and in Philosophy from Holy Cross in the United States.

Mike Motion is responsible for Bead Products’ sales and marketing. He has experience in both devices and drugs having previously been European Director of Oncology with Baxter Healthcare Limited. He has a BSc in Pharmacy.

Alistair Taylor is responsible for the regulatory affairs activities for all programmes within the Group. He obtained a BSc in Applied Chemistry, an MSc in Colloid and Interface Science and a PhD on the Behaviour of Artificial Tears on the Human Cornea from the University of Strathclyde, Scotland.

Geoff Tompsett joined Biocompatibles in January 2001 as Group Information Technology Director having previously held senior IT roles at Sanofi-Synthelabo and Sterling Winthrop, gaining a broad base of experience as business partner and programme manager. Since joining Biocompatibles, Geoff has added responsibility for Human Resources. Geoff is a Chartered Fellow of the Chartered Institute of Personnel Development.

Gary Lamoureux is the Founder of the BrachySciences group of companies. Over the past ten years he has successfully built a profitable business based on a series of valuable innovations coupled with high quality manufacturing and operations. He brings his expertise as Entrepreneur, Inventor and Strategic Business Visionary to the Biocompatibles’ team. In addition to his role within BrachySciences Gary is contributing to Business Development in North America at the group level. Gary has an MBA from the University of Connecticut.

Jim Matons manages the Oxford facility and is responsible for delivering the Company’s Brachytherapy business plan. He developed the commercial arm of BrachySciences which has successfully established itself as an innovative leader in the industry. Prior to joining the BrachySciences Group he held a succession of commercial roles with Amersham plc and later Oncura, Inc. (GE). Jim was also the founding Chairman of the brachytherapy industry association: the Coalition for the Advancement of Brachytherapy.

Peter Geigle is one of the founding shareholders of CellMed AG. Peter has a medical degree from the Johann Wolfgang Goethe University in Frankfurt. His specialisation is the collection and engineering of human cells.

Olaf Althaus is one of the founding shareholders and a member of the Management Board of CellMed AG. Olaf has a degree in Business and Engineering from the University of Karlsruhe. Before founding CellMed AG he was active as an investment banker in Frankfurt and London.